Last10K.com

Zymeworks Inc. (ZYME) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

Zymeworks Inc.

CIK: 1403752 Ticker: ZYME
Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Feb. 27, 2020
Jun. 30, 2019
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2019  
Document Fiscal Year Focus2019  
Document Fiscal Period FocusFY  
Entity Registrant NameZYMEWORKS INC.  
Trading SymbolZYME  
Entity Central Index Key0001403752  
Current Fiscal Year End Date--12-31  
Entity Current Reporting StatusYes  
Entity Filer CategoryLarge Accelerated Filer  
Entity Small Businesstrue  
Entity Shell Companyfalse  
Entity Emerging Growth Companyfalse  
Entity Address, State or ProvinceBC  
Entity Interactive Data CurrentYes  
Title of 12(b) SecurityCommon Shares  
Security Exchange NameNYSE  
Entity Common Stock, Shares Outstanding 45,518,869 
Entity Voluntary FilersNo  
Entity Well-known Seasoned IssuerYes  
Entity Public Float  $ 851.7
Entity File Number001-38068  
Entity Incorporation, State or Country CodeCA  
Entity Tax Identification Number47-2569713  
Entity Address, Address Line OneSuite 540—1385 West 8th Avenue  
Entity Address, City or TownVancouver  
Entity Address, Postal Zip CodeV6H 3V9  
Local Phone Number678-1388  
City Area Code604  
Document Annual Reporttrue  
Document Transition Reportfalse  

View differences made from one year to another to evaluate Zymeworks Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Zymeworks Inc..

Continue

Assess how Zymeworks Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Zymeworks Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Financial Instruments - Schedule Of Changes In Fair Value Of Warrant Liabilities (Detail)
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Redeemable Convertible Preferred Shares And Shareholders' Equity
Consolidated Statements Of Loss And Comprehensive Loss
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Additional Information (Detail)
Financial Instruments - Schedule Of Changes In Fair Value Of Liability Classified Stock Options (Detail)
Financial Instruments - Schedule Of Financial Liabilities Measured At Fair Value On A Recurring Basis (Detail)
Financial Instruments - Summary Of Changes In Fair Value Of The Company's Liability For Contingent Consideration (Detail)
Government Grants And Credits
Government Grants And Credits (Tables)
Government Grants And Credits - Additional Information (Detail)
Government Grants And Credits - Component Of Government Grants And Credits (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Income Tax Expense (Recovery) (Detail)
Income Taxes - Schedule Of Reconciliation Of Beginning And Ending Amounts Of Unrecognized Tax Benefits (Detail)
Income Taxes - Summary Of Expiry Details Of Investment Tax Credits, Non-Capital Losses And Net Operating Losses For Income Tax Purposes (Detail)
Income Taxes - Summary Of Significant Components Of Deferred Income Tax Assets And Liabilities (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Schedule Of Intangible Assets (Detail)
Ipr&Amp;D And Goodwill
Ipr&Amp;D And Goodwill (Tables)
Ipr&Amp;D And Goodwill - Additional Information (Detail)
Ipr&Amp;D And Goodwill - Summary Of Carrying Value Of Ipr&Amp;D, Net Of Impairment (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Schedule Of Balance Sheet Classification Of Lease Liabilities (Detail)
Leases - Schedule Of Future Minimum Lease Payment Operating Lease Liabilities (Detail)
Leases - Schedule Of Maturities Of Finance Lease Liabilities (Detail)
Liabilities
Liabilities (Tables)
Liabilities - Schedule Of Accounts Payable And Accrued Expenses (Detail)
Liabilities - Schedule Of Other Long-Term Liabilities (Detail)
Nature Of Operations
Nature Of Operations - Additional Information (Detail)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Summary Of Calculation Of Diluted Loss Per Share (Detail)
Other Expense, Net
Other Expense, Net (Tables)
Other Expense, Net -Schedule Of Other Non Operating Income Expense (Details)
Payment Of Long-Term Debt And Exercise Of Liability Classified Warrants
Payment Of Long-Term Debt And Exercise Of Liability Classified Warrants (Tables)
Payment Of Long-Term Debt And Exercise Of Liability Classified Warrants - Perceptive Debt - Additional Information (Detail)
Payment Of Long-Term Debt And Exercise Of Liability Classified Warrants - Summary Of Debt (Detail)
Property And Equipment
Property And Equipment (Tables)
Property And Equipment - Additional Information (Detail)
Property And Equipment - Components Of Property And Equipment (Detail)
Recent Accounting Pronouncements
Recent Accounting Pronouncements (Tables)
Recent Accounting Pronouncements - Impact Of The Adoption Of Topic 842 On Balance Sheet (Detail)
Recent Accounting Pronouncements - The Impact Of The Adoption Of Topic 842 On The Accompanying Condensed Consolidated Statements Of Operations (Detail)
Research, Collaboration And Licensing Agreements
Research, Collaboration And Licensing Agreements (Tables)
Research, Collaboration And Licensing Agreements - Additional Information - Beigene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Celgene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Iconic (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Janssen (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Leo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Merck (Detail)
Research, Collaboration And Licensing Agreements - Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions (Detail)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Additional Information (Detail)
Shareholders' Equity - Schedule Of Estimated Fair Value Of Stock Options Assumptions (Detail)
Shareholders' Equity - Schedule Of Non-Vested Stock Option Activity (Detail)
Shareholders' Equity - Schedule Of Stock-Based Compensation Expense For Equity Classified Instruments (Detail)
Shareholders' Equity - Summary Of Stock Options Granted (Detail)
Short-Term Investments
Short-Term Investments - Additional Information (Detail)
Subsequent Event
Subsequent Event - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Summary Of Estimated Useful Lives (Detail)
Ticker: ZYME
CIK: 1403752
Form Type: 10-K Annual Report
Accession Number: 0001193125-20-058902
Submitted to the SEC: Mon Mar 02 2020 4:14:27 PM EST
Accepted by the SEC: Mon Mar 02 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/zyme/0001193125-20-058902.htm